C
entral and peripheral mechanisms maintaining T cell tolerance to self Ags are variable in degree of completeness, and autoreactive T cells populate the peripheral immune system. Central tolerance in the thymus is largely governed through the interaction of the TCR with self-peptide-MHC complexes, in which high-avidity T cells are eliminated through apoptosis (1-3) or potentially differentiated into CD4 ϩ CD25 ϩ Foxp3-expressing regulatory T cells (Treg) 3 (4, 5) . Strategies by which autoreactive T cells may escape central tolerance to self Ags include down-modulation of receptor or costimulatory molecules (6) and skewing of CD4/CD8 coreceptor expression (7, 8) . These mechanisms are incomplete, however, such that self reactivity by some peripheral T cells is an intrinsic property of normal immunity, perhaps required to enable the immune repertoire to respond to the diverse nature of foreign Ags (9) .
Once in the periphery, several additional mechanisms operate as checkpoints to limit T cell activation to self Ags, including functional inactivation or anergy of the T cell (10, 11) , activationinduced T cell deletion (12) (13) (14) , generation of suppressive cytokine-secreting T cells (Tr1 and Th3) (15, 16) , and differentiation of uncommitted T cells into Foxp3-expressing regulatory T cells (17, 18) .
While several TCR transgenic mice have been developed to study tolerance to self Ags, the vast majority of studies use either alloreactive T cells or a foreign Ag-reactive T cell expressed as a TCR transgene along with the foreign Ag as a second transgene (4, 19, 20) . In human type 1 diabetes (T1D), HLA-DR4 subjects commonly carry peripheral T cells reactive to a variety of islet-associated self Ags, including the immunodominant glutamic acid decarboxylase (GAD)65 555-567 peptide, a naturally processed epitope of glutamic acid decarboxylase (21) (22) (23) (24) . Interestingly, recognition of this epitope displays a biased TCR repertoire, with prevalent use of V␤5.1/V␣12.1, although CDR3 regions are variable (22) . To study tolerance mechanisms associated with this dominant autoreactive specificity, we introduced transgenic TCR from two human CD4 ϩ T cells specific for GAD65 [555] [556] [557] [558] [559] [560] [561] [562] [563] [564] [565] [566] [567] , which differ only in their CDR3 regions, intercrossed into HLA-DR4 transgenic mice. Despite the close structural features of these two autoreactive TCR, stark differences in both central and peripheral tolerance mechanisms were elicited.
Materials and Methods
Mice DR0401-IE mice (DR4) were obtained from Taconic. These C57BL/6 IAb o/o mice express a human-mouse chimeric class II molecule in which the TCR-interacting and peptide-binding domains of mouse I-E (domains ␣ 1 and ␤ 1 , exon 2 in both genes) have been replaced with the ␣ 1 and ␤ 1 domains from DRA1*0101 and DRB1*0401, respectively. Retention of the murine ␣ 2 and ␤ 2 domains allows for the cognate murine CD4-murine MHC interaction (25) .
TCR sequences for generation of the two T cell transgenic mice were obtained from human CD4
ϩ T cell clones 164 (26)and 4.13 (22) . Both human T cells are responsive to the same self Ag GAD65 555-567 and both use human V␣12.1/V␤5.1 T cell receptors. The 164 T cell was cloned from peripheral blood from an HLA DRA1*0101/B1*0401 diabetes at-risk individual as previously described (26) . Clone 4.13 was cloned from the peripheral blood of an HLA DRA1*0101/B1*0401 diabetic individual (22) . Human-mouse chimeric TCR transgenes were constructed by subcloning PCR amplified regions encoding rearranged V␣J␣ and V␤D␤J␤ domains from the human clones into pT␣cass and pT␤cass TCR transgenic vectors, respectively (27) . TCR transgenic vectors pT␣cass and pT␤cass contain the natural mouse TCR ␣ and ␤ promoter/enhancer elements and mouse C␣ and C␤ constant regions, respectively. DNA injection into C57BL/6/I-Ab o/o (164 TCR) or F1-B6/ C3H (4.13 TCR) mouse embryos was performed at the University of Washington (Seattle, WA) in the Comparative Medicine Animal Facility. Founder mice containing the human TCR transgenes were then crossed onto DR0401-IE mice to generate DR4/164 and DR4/4.13 mice. Additional crosses were made onto Rag2 o/o mice. A founder mouse was also identified that contained only the 164 TCR ␤ transgene. This was also crossed onto DR0401-IE mice. The 4.13 TCR transgenic mice generated in F1-B6/C3H were crossed for nine generations into DR0401-IE mice. All animal work was approved by the Benaroya Research Institute Animal Care and Use Committee and animals were housed in the Benaroya Research Institute American Association of Laboratory Animal Care-accredited animal facility.
Tissue processing and flow cytometry
Thymus, spleen, and lymph node tissues were processed into single-cell suspensions by gently pressing through 0.40-m cell strainers (BD Falcon; ref. no. 352340) using the rubber end of a 1-ml tuberculin syringe in DMEM-10 media (Invitrogen; catalog no. 11965-092) supplemented with 10% FBS (HyClone), 100 g/ml penicillin, 100 U/ml streptomycin, 50 M 2-ME, 2 mM glutamine, and 1 mM sodium pyruvate (Invitrogen). Cell suspensions were centrifuged at 200 ϫ g for 10 min, aspirated, and either 1) resuspended in DMEM-10 media (lymph node and thymus) or 2) RBC were lysed (for spleens) using 1 ml of ACK lysis buffer (28) for 5 min at 37°C at which time 30 ml of media was added and cells spun down (200 ϫ g), aspirated, and resuspended in DMEM-10 media. The following chromophore-labeled Abs were used in flow cytometric analysis: anti-mouse CD4 (clone RM4-5), CD8 (clone 53-6.7), CD25 (clone PC61), CD62L (Mel-14), anti-human active caspase-3 (polyclonal, catalog no. 557091), CD44 (IM7), Fc block (2.4G2), and PE-labeled annexin V (all from BD Pharmingen), anti-human V␤5.1-PE (clone IMMU 157; Immunotech/ Coulter), and V␣12.1-FITC (clone 6D6; Endogen). FACS samples in media were prestained with Fc block for 10 min on ice and then stained with specific Abs on ice for 45 min, washed once, and resuspended in FACS stain buffer (PBS containing 1% FBS, 0.1% Na azide) before being run on a FACSCalibur or LSR II flow cytometer (BD Biosciences). Intracellular staining of cells for Foxp3 was performed using eBioscience kit (FJK.16a Ab) according to the manufacturer's instructions. Intracellular staining for active caspase-3, mouse anti-IFN-␥ (XMG1.2; eBioscience), and anti-IL-10 (clone JES5-16E3; eBioscience) was performed using eBioscience intracellular staining kit (catalog no. 88-8823-88; eBioscience).
Proliferation assays
In lymph node or purified CD4
ϩ T cell proliferation assays 1 ϫ 10 5 lymph node cells were cultured with 2 ϫ 10 5 (3000 rad) Cs-gamma-irradiated splenocytes (final volume 150 l). Supernatants for cytokine analysis were taken (50 l) at 48 h, and 1 Ci/well [ 3 H]thymidine was added at 72 h. Thymidine incorporation was assayed at 96 h using liquid scintillation counting analyzed on a Microbeta TriLux 1450 scintillation counter (Wallac-PerkinElmer Life Sciences). Splenocyte responses were measured in the same manner using 5 ϫ 10 5 splenocytes per well. CD4 and CD8 singlepositive cells were obtained using Mitenyi Biotec beads with purity of 90% or greater or by Ab labeling with CD4 and CD8 and sorting by flow cytometry.
Cytokine analysis
Cytokines IL-2, IL-4, IL-5, TNF-␣, and IFN-␥ were assayed using a mouse Th1/Th2 cytokine CBA kit (BD Biosciences; catalog no. 551287). IL-10 was assayed using a BD OptEIA mouse IL-10 ELISA set and mouse TGF-␤1 was measured using a human/mouse TGF-␤1 ELISA Ready-SETGo! kit (BD Biosciences; catalog nos. 555252 and 88-7344, respectively). Supernatants from triplicate proliferation wells (50 l/well) were combined for cytokine analysis, with 50 l used for CBA analysis and 50 l for IL-10 ELISA.
Results

Thymic selection of autoreactive T cells
Utilizing TCR from two structurally related DRB1*0401 (DR4) restricted human CD4 ϩ T cell clones reactive to the autoantigen GAD65, human TCR transgenic mice were generated to investigate differential modes of T cell tolerance to the naturally processed GAD65 555-567 autoantigen. The human CD4
ϩ T cell clones 164 and 4.13 (obtained from two different subjects) are structurally related in that they both use TCR with human V␣12.1 (hV␣12.1) and V␤5.1 (hV␤5.1) gene sequences, which differ only in their CDR3 regions (Table I ). Both of the human T cells recognize GAD65 555-567 (22, 26) , a region within the naturally processed and presented GAD65 552-572 epitope (21, 23) . The sequence of the DR4-binding minimal stimulating epitope GAD65 555-567 is identical for GAD65 and GAD67 in both human and mouse and thus serves as a naturally processed self Ag T cell epitope in both species (29) . Both 4.13/Rag2 ϩ/ϩ and 164/Rag2 ϩ/ϩ mice display reduced thymus cellularity ( Fig. 1A) , with 164 mice exhibiting a profound reduction in CD4 ϩ CD8 ϩ double-positive cells (Fig. 1B) . The reduction in cellularity and a decrease in double-positive cells is indicative of negative selection (20, 30, 31) . While positively 
a Gray highlighted areas denote differences between 164 and 4.13 TCR CD3 sequences; boldface, nonpolar-to-nonpolar amino acid changes; underlined residues, polar-to-polar changes; and parentheses, charge changes. Ϫ CD8 ϩ and CD4 ϩ CD8 Ϫ phenotypes, a profile similar to that observed in other self Ag-responsive TCR transgenic mice under conditions of strong negative selection (8) . In addition to the stronger negative selection observed in 164 mice is the down-modulated expression of the TCR on CD4 ϩ CD8 Ϫ thymocytes where only ϳ1% of mature CD4 ϩ CD8 Ϫ T cells express both V␣ and V␤ transgenes (Fig. 1C) . This is in stark contrast to the Ͼ70% expression of hV␣12.1 and hV␤5.1 on CD4 ϩ CD8 Ϫ thymocytes from 4.13 mice. As the amino acid sequence in the CDR3 region of 164 TCR is different from 4.13 TCR, it was possible that the low level of hV␤5.1 and hV␣12.1 staining on 164 mice could be the result of differential binding of the Ab itself; however, the hV␤5.1 Ab does stain the 164 TCR from 164 ␤-chain-only TCR transgenic mice (lacking the human TCR V␣12.1 transgene), suggesting that the low level of 164 TCR expression on matured CD4 ϩ CD8
Ϫ thymocytes is the result of down modulation of the TCR under thymic selection pressures (Fig. 1D ). Based on thymic cellularity, CD4 vs CD8 profiles, and TCR expression levels, we conclude that 164 TCR thymocytes, likely due to a higher avidity for peptide-MHC of the 164 TCR relative to the 4.13 TCR, undergo stronger central tolerance and maintain a down-modulated TCR.
Peripheral skewing of autoreactive T cells
4.13/Rag2
ϩ/ϩ and 164/Rag2 ϩ/ϩ mice both show reduced cellularity in the spleen ( Fig. 2A) , but only 164 mice show a reduction in peripheral lymph nodes. The 4.13 T cells in the spleen as in the thymus are heavily skewed toward CD4 ϩ CD8 Ϫ lineage, reflecting their class II restriction (Fig. 2B) Ϫ cells, which is also greater than that seen in non-TCR transgenic mice (Fig. 2B) . The percentages of CD4 cells among all T cells (CD4/(CD4 ϩ CD8)) (average of three mice) are 98 Ϯ 1% in 4.13 mice and 73 Ϯ 2% in 164 mice compared with 90 Ϯ 1% in non-TCR transgenic mice, indicating that 4.13 T cells are strongly selected toward their MHC class II restriction, while T cell selection in 164/Rag2 ϩ/ϩ mice is skewed toward the CD8 compartment, similar to what is observed in the thymus. The stronger central tolerance in 164/Rag2 ϩ/ϩ mice is also reflected in the periphery by the greater expression of endogenous mouse mV␣ and mV␤ T cell receptors (supplemental Fig. S1 ). 4 In assaying for Ag specificity we used splenocytes from Rag2 o/o TCR transgenic mice to ensure that all ␣/␤ T cells only express the hV␣12.1 and hV␤5.1 transgenes. Splenocytes from both 4.13/Rag2 o/o and 164/ Rag2 o/o mice respond to GAD65 555-567 in an Ag-specific manner, confirming their specificity for the GAD65 epitope (Fig. 2C) (Fig. 2D) . 4 The online version of this article contains supplemental material. 
Peripheral tolerance mediated by apoptosis
As with the low expression of the transgenic TCR on 164/Rag2 ϩ/ϩ thymocytes in the thymus (Fig. 2B) (Fig. 3, A and  B) . A similar activation profile of 164/Rag2 o/o CD4 ϩ T cells was observed in other lymph nodes (pancreatic and inguinal, data not shown) and also in Rag2 ϩ/ϩ mice (supplemental Fig. S3 ). Therefore, we tested whether the low numbers of T cells in the peripheral tissues of 164/Rag2 o/o mice could be the result of constant peripheral activation and subsequent activation-induced cell death. As shown in Fig. 3C ϩ , suggesting that apoptotic signaling may occur through CD95 (Fig. 3E) . 
ϩ cells that express Foxp3 participate in immune regulation, and the selection of these Treg can be mediated in foreign Ag-specific TCR transgenic mice by expression of the stimulatory Ag as a neo-self peptide driven by tissue-specific promoters (4, 32) . It has also been shown that increasing avidity of the TCR for the peptide-MHC correlates with a propensity to develop along the thymic-derived Foxp3 Treg pathway (4). In our setting involving endogenous self Ag recognition, we find that peripheral CD4 ϩ T cells from both autoreactive 4.13/Rag2 ϩ/ϩ and 164/Rag2 ϩ/ϩ TCR transgenic mice express increased numbers of Foxp3 cells, and that the percentage of CD4 ϩ cells that express Foxp3 is highest in 164 mice compared with 4.13 mice, and both are greater than that seen in non-TCR transgenic mice (Fig. 4B) . However, upon crossing TCR transgenic mice onto a Rag2-deficient background, peripheral Foxp3 ϩ cells were near undetectable levels in either 164 or 4.13 mice (Fig. 4C) , consistent with the induction of Treg populations in the nontransgenic fraction of endogenous T cells. mice were FACS sorted and stimulated with irradiated APC, and then assayed for IL-10 and IFN-␥ production. The 4.13 CD4 ϩ T cells from spleen generated IL-10 and IFN-␥ in response to either CD3/CD28 or GAD65 552-572 stimulation, while thymus-derived CD4 ϩ CD8 Ϫ 4.13 T cells secreted neither cytokine (Fig. 7) .
Discussion
Limiting pathogenic autoreactivity is of the utmost importance for a successful immune system, and several mechanisms provide functional checkpoints for this control. These mechanisms broadly fit into three categories: those that involve deletion of autoreactive cells, centrally and/or peripherally; those that involve down-modulation of activation molecules or receptors, changing activation thresholds; and those that involve active immune regulation. In this study we evaluated central and peripheral tolerance mechanisms using two TCR transgenic mice containing structurally similar receptors specific for a naturally processed self Ag. These TCR were derived from autoreactive CD4 ϩ T cells present in humans with immunity to GAD65, an important islet Ag associated with autoimmune diabetes. On a C57BL/6 "diabetes-resistant" background transgenic for HLA-DR4, the human class II-restricting element for these TCR, very potent in vivo tolerance mechanisms were observed. The 164 TCR was associated with strong deletional events, both in the thymus and in the periphery, and surviving 164 T cells down-modulated TCR expression and/or switched from CD4 to CD8 phenotype, even as they maintained specific Ag reactivity. In marked contrast, the 4.13 TCR had less sensitivity to negative selection and no CD4-to-CD8 skewing, but instead used a predominant pathway of immunomodulation, skewing toward an IL-10 phenotype.
Both 164 and 4.13 T cells use V␣12.1/V␤5.1 TCR and differ only in CDR3, a region that conventionally interacts primarily with the peptide in the Ag-binding MHC (33) . Based on the higher thymic cellularity in 4.13 mice compared with 164 mice and the absence of differentiation toward the CD4 Ϫ CD8 ϩ pathway, it appears that the 164 TCR is of a higher avidity to peptide-MHC complexes in the thymus. As T cell CD4 avidity interaction with the ␤ 2 domain of the MHC class II has been shown to contribute positively to thymic T cell selection (21, 34) The skewing of class II-restricted self Ag-reactive T cells toward a CD8 lineage has been observed in other TCR transgenic models, also in the context of strong negative selection (7, 8) .
In addition to thymic deletion and CD4-to-CD8 skewing, T cells surviving in the 164 TCR mice showed significant down-regulation of the TCR molecule itself. This also is consistent with a strategy invoked for lowering avidity, and correlated in the mice with evidence of a very strong activation-induced cell death pathway. The end result of all these simultaneous high-avidity tolerance checkpoints was the presence in the peripheral circulation of a low number of autoreactive T cells, which nevertheless displayed strong Ag-specific proliferative and Th1 characteristics.
Considering that both 164 and 4.13 TCR use V␣12.1 and V␤5.1 and are responsive to the same Ag, it was remarkable that 4.13 T cells showed a completely different tolerance induction profile. A more modest central tolerance for 4.13 T cells was reflected in less thymic deletion and normal CD4 ϩ CD8 Ϫ maturation, and similarly no evidence for peripheral activation-induced cell death or receptor down-modulation was observed. A likely explanation for the absence of peripheral activation of 4.13 T cells was the peripheral generation of IL-10-producing Tr1 regulatory cells in these mice. IL-10 is a potent regulatory cytokine and has been shown to be important in regulating colitis and autoimmunity in experimental autoimmune encephalomyelitis and collagen-induced arthritis models (35) (36) (37) (38) . The absence of IL-10 from sorted CD4 ϩ CD8 Ϫ T cells from the thymus upon stimulation with either CD3/CD28 or Ag-specific GAD65 552-572 peptide also indicates that generation of these IL-10-secreting T cells was a peripheral differentiation event. It is interesting to speculate that T cell-generated IL-10 in 4.13 mice could be preventing the activation of 4.13 T cells in the periphery, which contrasts with the activated phenotype in peripheral 164 mice. This hypothesis is currently being testing by crossing DR4/4.13/Rag2 o/o mice onto IL-10-deficient mice. While both 164 and 4.13 peripheral T cells are specific for GAD65 555-567 , because many TCR are degenerate in peptide recognition (39), we cannot exclude the possibility that cross-reactivity with other unknown ligands might contribute to the differences in functional profiles.
In the periphery, both 4.13 and 164 mice show an increase in Foxp3 ϩ cells, which is consistent with that seen in quasi-self Ag models (4, 40) . The larger increase in the percentage of Foxp3 ϩ cells in 164 mice relative to 4.13 mice correlates with the increase in negative selection (higher avidity TCR) in the thymus. However, upon crossing to Rag2-deficient mice we did not detect peripheral CD4 ϩ CD25 ϩ (Foxp3 ϩ ) cells from either 164 or 4.13 mice. This is in contrast to HA-specific and OVA-specific TCR transgenic mice on a Rag-deficient background where the Ag is expressed as a neo-self Ag (40 -42) . In these models up to half of peripheral T cells are CD25
ϩ and have a regulatory function. However, in TCR transgenic mice where the T cell-responsive Ag is endogenously expressed, CD4 ϩ CD25 ϩ (Foxp3 ϩ ) Treg do not develop on a Rag-deficient background. This includes a myelin basic protein-specific TCR (43) and the BDC2.5 TCR (44) . It has been suggested that a high-avidity interaction between T cells and APC in the thymus is required for Treg development (45) . Considering the strong negative selection in the thymus of both TCR mice suggesting a high functional avidity of the TCR for MHCAg, we were surprised to not find CD4 ϩ
CD25
ϩ Foxp3 ϩ cells in the periphery on Rag2 o/o mice. A possible explanation for a lack of Foxp3 ϩ Treg in these mice may be that both of these TCR are of high enough avidity that they are beyond the threshold for Foxp3 differentiation (5) .
Peripheral tolerance methods of anergy (10, 11) , deletion (12) (13) (14) , or the generation of Tr1 (15) and Th3(16) cells are a second line of defense against T cell autoimmunity. Once in the periphery 164 cells displayed a strong activation phenotype in both spleen and lymph nodes resulting in continued down-modulation of their TCR and concomitant activation-induced cell death through an activated caspase-3 pathway. Consistent with this is the expression of CD95 (FAS) on 164 T cells through which signaling has been shown to mediate deletion-induced peripheral tolerance (46, 47) . The 4.13 T cells, which populate the periphery to a greater extent, do not undergo this type of peripheral tolerance, most likely due to their apparent lower overall pMHC avidity.
Autoreactive cells, such as those used to derive the 164 and 4.13 TCR in this study, occur frequently in humans with autoimmune disease, in people who are genetically at risk of autoimmune disease, and in normal HLA-matched individuals (48 -52) . Nevertheless, overt autoimmune disease is relatively rare, reflecting the importance of tolerance checkpoints in normal immune function. Our study, using human autoimmune TCR and human MHC transgenic mice, directly demonstrates multiple mechanisms that, sometimes simultaneously, elicit both central and peripheral tolerance. Indeed, the two structurally similar TCR used, derived from human HLA-DR4 subjects, with specificity for the same Ag and restriction element and differing only in their CDR3 regions, revealed stark differences in deletional, compensatory, and immunomodulatory mechanisms. That such distinction occurs even with closely related autoreactive TCR underscores the importance of understanding the contribution of this variation to disease susceptibility, pathogenic pathways, and response to therapy. Va3. Supplemental Figure S2 
